Kansun Biopharma

Kansun Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative biologics for oncology and immunology. The company's research and development efforts center on multi-functional fusion proteins and next-generation monoclonal antibodies designed to modulate the tumor microenvironment. Its lead program, KS-001, is a bifunctional fusion protein targeting PD-L1 and TGF-beta, currently undergoing clinical evaluation for advanced solid tumors to overcome resistance to current checkpoint inhibitors. Kansun's broader pipeline includes candidates targeting CD47, LAG-3, and TIGIT, reflecting a strategic focus on synergistic combination therapies. The company aims to address significant unmet clinical needs through its proprietary technology platforms and global development strategy.